Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
Levodopa-induced dyskinesias represent a major shortcoming of Parkinson's disease management, and its pharmacological treatment is generally unsatisfactory. However, the conclusive demonstration of the benefits associated with early prescription of a dopamine agonist, the antidyskinetic properties of 'old' antiparkinsonian compounds such as amantadine, and the striking results of functional stereotatic neurosurgery are extremely important advances for the treatment of levodopa-induced dyskinesias.
Ferreira
J J
JJ
Clinical Investigation Centre, University Hospital, Toulouse, France.
Rascol
O
O
D000978:Antiparkinson Agents / Q000009:adverse effects*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D009069:Movement Disorders / Q000188:drug therapy / Q000517:prevention & control* / Q000601:surgery / Q000628:therapy*; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D007980:Levodopa